Petrovax completed Grippol® plus vaccine supplies to Russian and EEU markets on schedule
Before the 2019-2020 epidemic season, Petrovax Pharm shipped more than 8 million shots of Grippol® plus influenza vaccine for the Russian out-of-pocket market and exports.
Despite acute time shortage because of the WHO’s[1] late announcement of the final virus strain composition for the forthcoming epidemic season, Petrovax Pharm’s many-year experience in a large-scale vaccine production and supplies provided for timely Grippol® plus shipments to all respective countries. Importantly, vaccine exports to Belarus, Kazakhstan, Kyrgyzstan, and Uzbekistan exceeded 6M shots. The influenza vaccine was exported to the Republic of Belarus and the Republic of Kazakhstan under the national immunization programs.
NPO Petrovax Pharm is the Russian largest vaccine manufacturer; for more than 10 years, the company has supplied Grippol® plus to Russia’s regions and foreign markets, including shipments under the national immunization programs.
About Grippol® plus
Grippol® plus is a state-of-the-art Russian subunit adjuvanted inactivated influenza vaccine; its high efficacy and safety profiles have been proved by many-year experience of mainstream use for ninfluenza prevention in adults and children aged 6+ months. The preservative-free product is manufactured in disposable syringes at a modern facility to the applicable Russian and international GMP standards. The key advantage of trivalent Grippol® plus vaccine is high efficacy and low reactogenicity. The use of azoximer bromide adjuvant boosts the immune response and provides for a three-fold antigen load reduction on the human body as compared to traditional technologies, i.e. the vaccine contains 15 µg of hemagglutinin antigen instead of 45 µg. This technology is unique worldwide and has been used for manufacturing Grippol®, Grippol® plus, and Grippol® Quadrivalent vaccines for more than 20 years.
Due to efficacy, a high quality, and a high safety profile, Grippol® plus has won recognition abroad and is being exported to the EEU countries and Iran. For the 10 years the vaccine has been on the market, it was successfully used for immunization of more than 135M people.
Grippol® plus composition is updated on an annual basis pursuant to the WHO recommendations for a current epidemic season. According to the WHO forecast, two new influenza virus A strains (H1N1 и H3N2) will be circulating in the forthcoming epidemic season. Grippol® plus has the virus strain composition recommended for trivalent vaccines as follows:
- A/Brisbane/02/2018 (H1N1)pdm09-like virus;
- A/Kansas/14/2017 (H3N2)-like virus;
- B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage).
[1] On March 21, 2019, the WHO announced the final composition of the influenza vaccines to be used in the Northern Hemisphere in the 2019-2020 influenza season. For details, go to the WHO website: who.int
